United States — Food and Drug Administration & AbbVie
11 shared events · Importance 6 · Last updated Jul 29, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The FDA is holding a public workshop to review testosterone evidence for menopausal women, which could shape future regulatory approval and market access.
AbbVie: AbbVie's AndroGel is among testosterone products used off-label by women, potentially benefiting from increased demand.
Sep 15, 2026 · 6 articles
Business
United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.
AbbVie: AbbVie is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA granted Fast Track designation to Varseta-M, facilitating its development and review for a serious condition with unmet medical need.
AbbVie: AbbVie, through its acquisition of ImmunoGen, is a collaborator in the discovery of Varseta-M, but this event has minimal direct impact on AbbVie.
Aug 27, 2026 · 6 articles
Business
United States — Food and Drug Administration: The Taiwan FDA granted marketing approval for QUVIVIQ, a regulatory milestone that enables commercialization in Taiwan.
AbbVie: AbbVie achieved third and fourth research milestones under its collaboration with Nxera, resulting in US$20 million in milestone payments to Nxera. This reflects progress in neurological disease programs.
Aug 07, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA classified the recall as Class II and issued public notices, reinforcing its regulatory oversight role.
AbbVie: AbbVie now owns the brand Pred Forte, but is not directly affected by the recall of the generic version.
Jul 07, 2026 · 38 articles
Business
United States — Food and Drug Administration: The USFDA conducted three inspections of Piramal Group facilities, all with zero Official Action Indicated observations. This outcome underscores Piramal Group's compliance and quality standards, which is positive for its regulatory standing and market reputation.
AbbVie: AbbVie is mentioned as a joint venture partner in Abbvie Therapeutics India Private Limited, an associate company of Piramal Group. The report does not detail any direct impact on AbbVie, but the association highlights a successful collaboration in the ophthalmology market.
Jul 20, 2026 · 12 articles
Business
United States — Food and Drug Administration: Piramal Group completed three USFDA inspections with zero OAI observations, reflecting strong quality standards.
AbbVie: AbbVie is a joint venture partner in Abbvie Therapeutics India Private Limited, mentioned as an associate company.
Jul 07, 2026 · 14 articles
Business
United States — Food and Drug Administration: The FDA approved Palsonify in 2025, enabling its commercial availability. The agency's regulatory decisions are relevant to the value of the acquired assets.
AbbVie: Mentioned as part of 2026 M&A activity; acquired Apogee for $10.9B.
Jul 06, 2026 · 34 articles
Business
United States — Food and Drug Administration: The FDA granted Breakthrough Therapy Designation to BPL-003 and announced regulatory actions to support psychedelic drug development, facilitating the path to market.
AbbVie: AbbVie is a competitor that previously acquired KC Pharmaceuticals for up to $1.2B in 2024, highlighting industry interest in psychedelic therapies.
Jul 16, 2026 · 25 articles
Business
United States — Food and Drug Administration: The US FDA issued an Establishment Inspection Report to Piramal Group's Sellersville facility, confirming quality compliance.
AbbVie: AbbVie is a joint venture partner in Abbvie Therapeutics India Private Limited, mentioned as an associate company.
Jul 29, 2026 · 10 articles
Tech
AbbVie: AbbVie Inc. is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.
Feb 19, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and AbbVie interact across events, view sentiment trends, and discover connected entities.
Open Dashboard